Recursion articles
The drug developer`s latest capital raise, a $150 million private placement, comes during a difficult market environment.
The strongest companies can raise money in any environment.
Recursion Pharmaceuticals (RXRX) - Get Free Report recently raised $150 million in gross proceeds from a private placement of
Maxx Chatsko
I’m Anne Carpenter, a member of Recursion’s Scientific Advisory Board since 2014, a few months after the company was launched. I read Chris’ blog post reflecting on Recursion’s early days and thought I could tell my side of the story: watching Recursion get off the ground.
I feel a bit sheepish as I recall grilling Recursion co-founders Chris Gibson and Blake Borgeson the day we first met in October 2013. I was almost seven years into leading my o
Anne Carpenter
By applying a proprietary operating system to drug discovery, the Utah clinical-stage biotechnology company expects to turn drug discovery from sequential testing into a search problem.
Unmet clinical needs often serve as the fundamental driving force behind drug discovery programs. During lead discovery, an intensive search ensues to find a drug-like small molecule or biological therapeutic, initially a hit that, through further validation and evolution, can become a develop
Jonathan D Grinstein
It was great to be back in person at the 2022 BIO International Convention this year. It came as no surprise to us at Recursion that artificial intelligence (AI) and machine learning (ML) were hot topics at the conference, with more than half a dozen sessions exploring how these technologies are driving digital transformation in biopharma.
We heard from leaders who are applying AI at various stages across the drug discovery and development process. While the app
Shafique Virani
Recursion is entering an exciting period in our evolution as a clinical-stage biotechnology company. We recently announced that we’ve enrolled the first patient in the first human efficacy trial in our company’s history — a significant milestone for us, and for the patients we hope to serve.
Our Phase 2 trial is investigating the treatment of a disease called cerebral cavernous malformation (CCM), a devastating neurovascular disease. This pr
Chris Gibson
I was born in a country at the intersection of Europe and the Middle East — both geographically and culturally. Turkey is a beautiful country, and also a challenging one in many aspects. My mom was not able to continue her education after fifth grade because the middle school for girls was miles away from her home. She has always been a big supporter of my education and career.
Growing up, I was interested in a wide variety of careers. I aspired to become an arche
Throughout my career, I always heard about finding your “dream job” but had honestly dubbed the concept a myth. I never imagined that one day, that myth would become my reality. On April 5th, 2021 my now-manager Ben Sukow called with a job offer that changed my perspective.
For almost a decade, I have wanted to work in the field of computational biology. I wanted to learn and grow in that space, and always hoped to work at a place where my contributions could impa
At Recursion, we are working to decode biology and industrialize drug discovery. We have successfully executed over 82 million phenomic experiments and inferred over 179 billion biological relationships in our quest to identify promising novel therapeutic approaches. Now, we are extending our industrialized approach to petabytes of pre-clinical in vivo studies. Digitalizing in vivo studies could further speed up our science by reducing the time need